Company: CRVO
Filing Date: 2025-05-12
Form Type: 424B5
Source: 0001437749-25-016167
Chunk: 8

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 424B5
Chunk 8
---
 of this prospectus supplement.                                                                                                                                                                   |
| Use of Proceeds:                         | We intend to use the net proceeds from this offering, if any, to fund research and development of our lead product candidate, neflamapimod, including clinical trial activities, and for other general corporate purposes, including working capital, capital expenditures and general and administrative expenses. See “Use of Proceeds.”                      |
| Risk Factors:                            | Investing in our common stock involves risks. See “Risk Factors” beginning on page S-6 of this prospectus supplement and under similar headings in the documents incorporated by reference herein for a discussion of the factors you should carefully consider before deciding to invest in our common stock.                                                  |
| NASDAQ Capital Market symbol:            | “CRVO”                                                                                                                                                                                                                                                                                                                                                          |

The number of shares of common stock to be outstanding after this offering as shown above is based on 8,702,719shares of our common stock outstanding as of March 31, 2025, and excludes:

| ● | 672,576 shares of common stock issuable upon the exercise of options outstanding under the CervoMed Inc. 2015 Equity Incentive Plan, as amended (the “2015 Plan”), as of March 31, 2025, with a weighted average exercise price of $11.93 per share; |

| ● | 165,160 shares of common stock issuable upon the exercise of options outstanding under the CervoMed Inc. 2018 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2018 Plan”), as of March 31, 2025, with a weighted average exercise price of $19.65 per share; |

| ● | 71,712 shares of common stock issuable upon the exercise of options issued as inducements material to new employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), as of March 31, 2025, with a weighted average exercise price of $12.40 per share; |

| ● | 67,316 shares of common stock that were reserved for issuance as of March 31, 2025 under our 2018 Plan; and |

| ● | 2,609,289 shares of common stock issuable upon exercise of outstanding warrants, at a weighted average exercise price of $39.58 per share. |

Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding stock options and warrants described above